July 19, 2012 (Atlanta) — Dr. Stephen M. Szabo and James Gilmore Jr., PharmD, of Georgia Cancer Specialists (GCS)—a Top 10 private cancer practice in the U.S.— published an article in the June issue of the journal Community Oncology on cancer recurrence and survival in patients with early-stage triple-negative breast cancer.
Published in the June online issue of the Community Oncology, the article relates outcomes of a study of data extracted from the 2003-2008 Georgia Cancer Specialist Database. The purpose of the study was to evaluate the impact of triple-negative (TN) status on disease recurrence and survival among stage I-III patients who were treated with adjuvant chemotherapy in a community-based clinical practice setting.
Triple-negative breast cancer (TNBC) has fewer treatment options than other forms of breast cancer and is associated with a poor prognosis in the metastatic and adjuvant setting.
Drs. Neal P. Christiansen of Hollings Cancer Center at the Medical University of South Carolina in Charleston, and Lei Chen of Sanofi US, in Bridgewater, New Jersey, were also cited as authors.
The study followed stage I-III breast cancer patients who received adjuvant chemotherapy from initial diagnosis until death, recurrence, or loss to follow-up. The article assessed the influence of TN status on disease-free survival (DFS) and recurrence.
The journal Community Oncology concentrates particularly on original research, rare cancers in the community setting, quality of care in community oncology, end-of-life care, community practice guidelines, practice management and reimbursement issues, and news from Washington and the US Food and Drug Administration.
Dr. Gilmore is Executive Vice President at GCS and oversees the pharmacy and research departments. Dr. Szabo practices at the GCS Gwinnett and Johns Creek offices.
Georgia Cancer Specialists is a Top 10 private cancer practice in the U.S. and a leader in advanced cancer treatment and research. The practice supports more than 200,000 patient visits each year. GCS offers community-based medical oncology and hematology services and is the first private oncology practice to also provide a full range of support services for patients in Georgia, including wellness counseling and home health coordination. The GCS research department, whose focus is bringing targeted cancer therapy to communities, is the first in Georgia to offer Phase I clinical trials, the most novel cancer therapies available. GCS has 27 offices, 45 physicians, and more than 500 support staff members located in Metro Atlanta, and North and Central Georgia. Georgia Cancer Specialists can be found on the web at www.gacancer.com GCS is The Cancer Answer.